Abstract
Subthreshold depression is a substantial risk factor for the development of major depression. It is associated with poorer health, functional disabilities, and reduced quality of life in older adults. There is a paucity of cost-effective psychosocial interventions for this population in primary care worldwide, particularly in low- and middle-income countries. We present a protocol for evaluating the effectiveness and cost-effectiveness of the Viva Vida programme, a 6-week self-help digital psychosocial intervention for treating older adults with subthreshold depressive symptoms in primary care with a two-arm, individually randomised controlled trial with a 1:1 allocation ratio with integrated economic and process evaluations. We will include 450 individuals 60 years and older with subthreshold depressive symptoms (score between five and below 10 on the 9-item Patient Health Questionnaire (PHQ-9)), registered with one of the 46 primary care clinics in Guarulhos, Brazil. The Viva Vida programme will be delivered via automated audio and visual WhatsApp messages, with psychoeducation and behavioural activation content. It involves 48 messages, delivered twice daily, four days a week. Participants in the control arm will receive a single message with general information about depression. The primary outcome is the depressive symptoms at the three-month follow-up as measured by PHQ-9, which will be compared between study arms. The cost-effectiveness of the intervention will be assessed at five months. A detailed process evaluation will explore context and implementation outcomes. The Viva Vida programme is an innovative digital psychosocial intervention delivered via WhatsApp messaging without the participation of health professionals. The evaluation of the Viva Vida programme will contribute to the development of simple and cost-effective models of remote self-help interventions for reducing depressive symptoms among older adults with subthreshold depression in primary care. The protocol is registered with Registro Brasileiro de Ensaios Clinicos (ReBEC) (RBR-6c7ghfd).
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
The protocol is registered with Registro Brasileiro de Ensaios Clinicos (ReBEC) (RBR-6c7ghfd).
Clinical Protocols
https://figshare.com/s/33a83alad01751dcf38c
Funding Statement
This study was funded by the Sao Paulo Research Foundation (process number 2017/50094 2) and the Joint Global Health Trials initiative, jointly funded by the Department of Health and Social Care (DHSC), the Foreign, Commonwealth & Development Office (FCDO), the Medical Research Council (MRC) and Wellcome (process number MR/R006229/1). MS is supported by the CNPq Brazil (307579/2019 0). FAPESP supported CAN (2018/19343 9 and 2022/05107 7), TVND (2021/04493 8), FAM (2020/02272 1), MOC (2020/14768 1), CHQS (2020/14504 4), GMO (2021/04230 7), MSS (2021/10148 1 and 2022/08668 0) and MMSM (2021/03849 3).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was authorised by the Secretaria da Saude do Municfpio de Guarulhos and approved by the Ethics Committee of the Hospital das Clfnicas da Faculdade de Medicina da Universidade de Sao Paulo - HCFMUSP (CAPPesq, ref: 4.144.603, first approval 9 July 2020). This is the protocol version 6.0, 24 March 2023.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Title modified. Abstract updated. All sections of the manuscript were updated. We included a few new pieces of information and changed some sentences without changing the content. The supplementary files S1 and S2 were updated, and we added one supplementary file (S5).
Data Availability
No datasets were generated or analysed during the current study. All relevant data from this study will be made available upon study completion.
